The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma
Urvi Shah, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the final results from a randomized investigator-initiated trial (NCT04497961) that evaluated single-agent daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma (MM). Dr Shah notes that this study provides evidence for the potential of daratumumab monotherapy as an effective maintenance strategy, particularly for patients who may not tolerate lenalidomide or prefer a monthly treatment option. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
